Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Drug Classification (First Generation, Second Generation ), By Region & Competition, 2021-2031F

The Global Antipsychotic Drugs Market is projected to expand significantly, growing from USD 15.78 Billion in 2025 to USD 26.33 Billion by 2031, at a robust Compound Annual Growth Rate (CAGR) of 8.91%. These essential psychiatric medications are primarily used to manage psychosis, including symptoms like delusions, hallucinations, and disorganized thought processes, commonly associated with conditions such as schizophrenia, bipolar disorder, and severe depression. This market's growth is fundamentally driven by the increasing worldwide prevalence of mental health conditions, enhanced diagnostic capabilities, and governmental efforts to reduce the stigma surrounding psychiatric care. These combined factors ensure a continuous demand for effective therapeutic interventions, underscored by the World Health Organization's projection that over 1 billion people globally will be living with a mental disorder by 2025, necessitating consistent long-term pharmacological management. However, a significant obstacle hindering market growth is the widespread occurrence of severe adverse effects linked to antipsychotic drugs, which include metabolic syndrome, weight gain, and tardive dyskinesia. These complications frequently lead to poor patient adherence and high rates of treatment discontinuation, thereby limiting the full commercial potential of current treatment regimens and creating barriers to stable revenue generation.

The prevalence of severe adverse effects associated with antipsychotic pharmacotherapy constitutes a critical barrier to the expansion of the Global Antipsychotic Drugs Market. Side effects such as metabolic syndrome, weight gain, and tardive dyskinesia significantly diminish the tolerability of these medications, forcing many patients to discontinue treatment prematurely. When patients experience debilitating physical complications alongside their psychiatric condition, their willingness to sustain long-term pharmacological regimens declines sharply. This interruption in therapy directly undermines the recurring revenue streams that pharmaceutical manufacturers rely upon, as the realization of commercial potential depends heavily on consistent, uninterrupted usage over a patient's lifetime.

Market Driver

The escalating global prevalence of schizophrenia and bipolar disorders serves as the primary catalyst propelling the antipsychotic drugs market. These chronic and debilitating conditions necessitate lifelong pharmacological management, thereby ensuring a consistent demand for antipsychotic therapeutics. As diagnostic criteria continue to improve and healthcare systems in emerging economies expand, the identified patient population requiring treatment steadily widens, directly translating into increased prescription volumes. According to the World Health Organization's 'Schizophrenia' fact sheet in October 2025, approximately 23 million people worldwide were affected by this disorder, highlighting the critical need for accessible therapeutic options and underpinning the sector's financial resilience, as evidenced by Otsuka Holdings' pharmaceutical segment revenue increasing by 17.1% in fiscal year 2024, largely driven by sustained global demand for its psychiatric medication portfolio.

Simultaneously, the accelerated adoption of Long-Acting Injectable (LAI) formulations is transforming the market landscape by effectively addressing the pervasive issue of patient non-adherence. By reducing the dosing frequency from daily oral intake to monthly or bi-monthly injections, LAIs significantly improve therapeutic outcomes and reduce relapse rates, encouraging clinicians to prioritize these formulations over traditional treatments. This clinical shift lowers discontinuation rates and fosters higher patient compliance, thereby ensuring consistent revenue streams for pharmaceutical manufacturers. Alkermes plc, for instance, reported in February 2025 that revenues for its proprietary LAI product ARISTADA grew 16% year-over-year to $96.6 million in the fourth quarter, illustrating the substantial commercial viability of this advanced delivery mechanism.

Market Challenge

The prevalence of severe adverse effects linked to antipsychotic pharmacotherapy presents a significant obstacle to the growth of the Global Antipsychotic Drugs Market. Side effects such as metabolic syndrome, weight gain, and tardive dyskinesia severely reduce the tolerability of these medications, frequently compelling patients to discontinue treatment prematurely. When individuals face debilitating physical complications in addition to their psychiatric condition, their motivation to maintain long-term pharmacological regimens sharply diminishes, directly disrupting the recurring revenue streams on which pharmaceutical manufacturers depend, as commercial success hinges on consistent, uninterrupted usage throughout a patient's life.

The economic repercussions of this non-adherence are substantial and directly impede market value. High rates of discontinuation lead to a reduction in the total volume of drug consumption, causing sales figures to stagnate despite the increasing global prevalence of mental disorders. Data from the National Community Pharmacists Association in 2025 indicated that up to 50% of patients with chronic conditions failed to take their medications as prescribed. This significant rate of non-compliance, largely driven by tolerability issues, restricts the market's capacity to fully capitalize on the diagnosable patient pool, effectively capping revenue generation and hindering overall industry advancement.

Market Trends

The emergence of antipsychotics utilizing novel non-dopaminergic mechanisms represents a significant market evolution, directly addressing the critical need for effective treatments with enhanced tolerability profiles. Unlike conventional agents that primarily block dopamine D2 receptors, which can lead to metabolic syndrome and motor side effects, this innovative class targets alternative systems, such as muscarinic acetylcholine receptors, to modulate psychotic symptoms. This paradigm shift is attracting substantial investment as manufacturers strive to capture market share from patients who discontinue standard therapies due to adverse events, exemplified by Bristol Myers Squibb's acquisition of Karuna Therapeutics for a total equity value of $14 billion in March 2024, underscoring the industry's massive financial commitment to these first-in-class non-dopaminergic therapies.

Concurrently, the expansion of indications for the adjunctive treatment of Major Depressive Disorder (MDD) is broadening the commercial horizon for third-generation atypical antipsychotics. As monotherapy antidepressants frequently fail to achieve remission in complex cases, clinicians are increasingly prescribing these agents as add-on therapies, effectively unlocking a patient population significantly larger than that of schizophrenia alone. This strategic label expansion enables pharmaceutical companies to maximize the lifecycle value of their assets and sustain growth, even amidst patent pressures in other portfolios. For instance, AbbVie reported in April 2024 that global net revenues for its flagship psychiatric drug Vraylar increased by 23.6% to $694 million, a surge largely driven by its growing adoption in the management of mood disorders, including its use as an adjunctive treatment for MDD.

Key Market Players

• Eli Lily and Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Johnson & Johnson
• Otsuka Pharmaceutical Co, Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Dr. Reddy's Laboratories Limited
• Otsuka Holdings Co., Ltd.
• Teva Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Antipsychotic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antipsychotic Drugs Market, By Application

• Schizophrenia
• Bipolar Disorder
• Unipolar Disorder
• Dementia
• Others

Antipsychotic Drugs Market, By Drug Classification

• First Generation (Typical)
• Second Generation (Atypical)

Antipsychotic Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antipsychotic Drugs Market.

Available Customizations:

Global Antipsychotic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).